April 22nd 2024
During a Community Case Forum live event in partnership with The Arizona Clinical Oncology Society, Felipe Batalini, MD, discussed the TROPiCS-02 trial of sacituzumab govitecan and the impact of the UGT1A1 status on adverse event frequency.
Medical Crossfire®: How Have HER2-Low Expressing Breast Cancers and Novel Advances in the Field Redefined Care As We Knew It?
View More
Community Practice Connections™: What’s Next for Patients with Breast Cancer, and How Can We Effectively Optimize PARP-, HER2/3-, and TROP2-Targeted Regimens in Treatment Plans?
View More
Patient, Provider and Caregiver Connection™: Addressing Patient Concerns During the Treatment and Management of HR+/HER2- Breast Cancer
View More
Show Me Your Care Plan: Nursing Considerations for Managing Breast Cancer Patients
View More
Community Practice Connections™: The Newest Frontier in HR+ Breast Cancer—Targeting ESR1 Mutations with Next-Generation Endocrine Therapy
View More
Clinical Case Vignette Series™: 40th Annual Miami Breast Cancer Conference®
View More
Oncology Consultations®: Next Generation SERDs—Key Data and Practical Takeaways for the Community Physician
View More
HER2+ Breast Cancer Tumor Board: Navigating Current and Evolving Strategies from Early Stages to Metastases
View More
Medical Crossfire®: Leveraging Multidisciplinary Teams in Early–Stage Breast Cancer When the Goal is Cure
View More
Show Me the Data®: Do We Have Sea Change for Novel Approaches in HR+/HER2- Breast Cancer? CDK, PI3K/AKT, ADC, and Next-Gen SERD Strategies Assessed
View More
Multidisciplinary Management of TNBC: Immunotherapy, PARP, TROP2, Oh My!
View More
23rd Annual International Congress on the Future of Breast Cancer® West
July 12-13, 2024
Register Now!
23rd Annual International Congress on the Future of Breast Cancer® East
July 19-20, 2024
Register Now!
Community Practice Connections™: The Advent of TROP2-Targeted Treatment Approaches in HR+/HER2- Breast Cancer
View More
Show Me the Data™: Do We Have Sea Change for Novel Approaches in HR+/HER2- Breast Cancer? CDK, PI3K/AKT, ADC, and Next-Gen SERD Strategies Assessed
View More
Community Practice Connections™: Controversies and Conversations About HER2- Expressing Breast Cancer…Advances in Management of HER2-Low to -Positive Disease
View More
Cancer Summaries and Commentaries™: Clinical Updates from Chicago in Breast Cancer
View More
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
Community Practice Connections®: Evaluating the Evolving Treatment Landscape for mHR+ Breast Cancer-How to Personalize Care and Improve Patient Outcomes
View More
Community Practice Connections™: Leveraging Multidisciplinary Teams in Early-Stage Breast Cancer When the Goal Is Cure
View More
Community Practice Connections™: 22nd Annual International Congress on the Future of Breast Cancer®
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
22nd Annual School of Breast Oncology
November 7-9, 2024
Register Now!
42nd Annual CFS®: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
Emerging Treatments and Evolving Paradigms in HER2-Low Breast Cancer
View More
Matching the Right Patients to the Right Therapies in TNBC: Case-Based Applications of Immune Checkpoint Inhibitors, PARP Inhibitors, and TROP2-Targeted ADCs
View More
Clinical Vignettes™: The Experts Explain How They Integrate PET Imaging into Metastatic HR+ Breast Cancer Care Settings
View More
Matching the Right Patients to the Right Therapies in TNBC: Case-Based Applications of Immune Checkpoint Inhibitors, PARP Inhibitors, and TROP2-Targeted ADCs
View More
School of Breast Oncology® Live Video Webcast: Clinical Updates from San Antonio
View More
PRESERVE 2 Trial of Trilaciclib Completes Enrollment of Patients With Metastatic TNBC
October 12th 2022The PRESERVE 2 trial evaluating trilaciclib in patients with metastatic breast cancer has finished enrolling patients. Results from the interim analysis of the trial is expected in the second half of 2023.
Read More
Roundtable Discussion: Examining Treatment Options After Adjuvant Chemotherapy for TNBC
October 10th 2022During a case-based roundtable event, Christos Vaklavas, MD moderated a discussion about treatment option for a 48-year-old woman with triple negative breast cancer following adjuvant chemotherapy.
Read More
Roundtable Discussion: Hamilton Compares Therapy Options and Sequencing for Recurrent TNBC
September 25th 2022During a Targeted Oncology case-based roundtable event, Erika P. Hamilton, MD, discussed the choice of first- and second-line therapy for a patient with triple-negative breast cancer following adjuvant chemotherapy.
Read More
KEYNOTE-522 Trial of Pembrolizumab Does Not Negatively Affect HRQOL Outcomes in TNBC
September 12th 2022Pembrolizumab in the neoadjuvant and adjuvant settings demonstrated similar health-related quality-of-life scores in patients with triple-negative breast cancer when compared with placebo.
Read More
Trastuzumab Deruxtecan Preserves QOL in HER2-Low Breast Cancer
September 11th 2022Patient-reported outcomes from the DESTINY-Breast04 trial showed a quality-of-life benefit from treatment with trastuzumab deruxtecan compared with physician’s choice of therapy in patients with hormone receptor–positive, HER2-low metastatic breast cancer.
Read More
Sacituzumab Govitecan Shows Strong ORR, PFS Benefit in HER2-Low/IHC0 Metastatic Breast Cancer
September 10th 2022The antibody-drug conjugate sacituzumab govitecan demonstrated superior overall response rate and progression-free survival in patients with breast cancer with limited options due to lack of high HER2 expression.
Read More
Lasofoxifene Improves Certain Responses in ESR1-Mutated, ER+/HER2- Metastatic Breast Cancer
September 10th 2022While lasfoxifene alone did not meet the primary end points that researchers set out for it, they did find that it improves responses in patients with estrogen receptor–positive, HER2-negative metastatic breast cancer harboring ESR1 mutations.
Read More
Dalpiciclib Improves PFS in the First-Line for HR+/HER2– Advanced Breast Cancer
September 9th 2022The phase 2 DAWNA-2 trial of dalpiciclib plus letrozole or anastrozole led to a reduced the risk of disease progression vs chemotherapy alone in patients with treatment-naïve, hormone receptor–positive, HER2-negative advanced breast cancer.
Read More
Adding Oleclumab to Durvalumab and Chemotherapy Does Not Reach Clinical Benefit in Advanced TNBC
September 9th 2022Oleclumab plus durvalumab and chemotherapy did not increase clinical benefit rate for patients with advanced triple-negative breast cancer, according to results from the phase 2 SYNERGY trial.
Read More
Sactiuzumab Govitecan Significantly Improves OS in Pretreated HR+/HER2- Metastatic Breast Cancer
September 9th 2022Treatment with sactiuzumab govitecan improved overall survival, objective response rate, duration of response, and overall quality of life vs physician’s choice in the phase 3 TROPiCS-02 study.
Read More
Abemaciclib Plus Aromatase Inhibitors Shows Improved OS in HR+/HER2- Breast Cancer
September 9th 2022Updated findings of the MONARCH 3 trial of abemaciclib added to a nonsteroidal aromatase inhibitor presented at ESMO 2022 revealed prolonged overall survival in hormone receptor-positive, HER2-negative breast cancer.
Read More
Sacituzumab Govitecan Improves PFS in HR+/HER2- Metastatic Breast Cancer
September 6th 2022Sacituzumab govitecan demonstrated promising progression-free survival efficacy in patients with HR+/HER2-low and IHC0 status metastatic breast cancer, showing its potential as a future treatment option.
Read More
Hormone Therapy Discontinuation Rates Differ From Those in Randomized Trials
August 29th 2022Hot flashes related to adjuvant hormone therapy were predictive of worse breast cancer outcomes, according to research on disease-free survival and treatment discontinuation in patients with and without hot flashes.
Read More
Roundtable Discussion: Reviewing Management Options for a Patient With TNBC
August 24th 2022During a Targeted Oncology case-based roundtable event, Alison K. Conlin, MD, discussed with participants their choice of first- and second-line therapy for a patient with triple-negative breast cancer.
Read More
Exploring Sacituzumab Govitecan and Other Second-Line TNBC Therapies
August 15th 2022During a live virtual event, Elizabeth Ann Mittendorf, MD, PhD, discussed the case of a patient with triple-negative breast cancer whose disease progressed following adjuvant dose-dense doxorubicin plus cyclophosphamide with paclitaxel, then frontline gemcitabine and carboplatin. This is the second of 2 articles based on this live event.
Read More
FDA Grants Priority Review to NDA for Elacestrant in ER+/HER2- Advanced or mBC
August 11th 2022Positive findings from the phase 3 EMERALD study led to a new drug application for elacestrant as treatment of estrogen receptor-positive, HER2-negative advanced or metastatic breast cancer. The FDA has granted the application priority review.
Read More